1. Transient reactivation of occult hepatitis B virus infection despite lamivudine prophylaxis in a patient treated for non-Hodgkin lymphoma
- Author
-
G. Tonziello, Giuseppe Pasquale, Salvatore Guastafierro, Antonello Sica, Evangelista Sagnelli, Caterina Sagnelli, Marintonietta Pisaturo, Maria Giovanna Ferrara, Nicola Coppola, Tonziello, G., Pisaturo, M., Sica, A., Ferrara, M. G., Sagnelli, C., Pasquale, G., Sagnelli, E., Guastafierro, S., Coppola, N., Tonziello, G, Pisaturo, M, Sica, A, Ferrara, Mg, Sagnelli, Caterina, Pasquale, G, Sagnelli, E, Guastafierro, S, and Coppola, Nicola
- Subjects
Occult HBV infection ,Microbiology (medical) ,Hepatitis B virus ,medicine.disease_cause ,Antiviral Agents ,Lamivudine prophylaxi ,Immunosuppressive disease ,immune system diseases ,hemic and lymphatic diseases ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Aged, 80 and over ,Antiviral Agent ,Antineoplastic Combined Chemotherapy Protocol ,business.industry ,Lymphoma, Non-Hodgkin ,Lamivudine ,Hepatitis B viru ,General Medicine ,Viral Load ,Hepatitis B ,medicine.disease ,Occult ,Lymphoma ,Discontinuation ,Onco-hematological disease ,Infectious Diseases ,DNA, Viral ,Immunology ,Female ,Virus Activation ,Rituximab ,business ,Viral load ,Human ,medicine.drug - Abstract
A female patient with non-Hodgkin lymphoma who tested positive for surface antigen of the hepatitis B virus and negative for hepatitis B core antibody experienced a reactivation of occult HBV infection 20 months after rituximab discontinuation despite lamivudine prophylaxis covering the 4 months of rituximab administration and the subsequent 12 months. © 2012 Springer-Verlag.
- Published
- 2012
- Full Text
- View/download PDF